Covered recipient · General Payments record
THOMAS P STERN
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$14,332.05
86 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,500.00 | 3 |
| Consulting Fee | $2,330.00 | 5 |
| Travel and Lodging | $1,339.77 | 18 |
| Food and Beverage | $1,162.28 | 60 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Avadel CNS Pharmaceuticals, LLC | $13,458.01 | 36 |
| JAZZ PHARMACEUTICALS INC. | $389.93 | 22 |
| GlaxoSmithKline, LLC. | $243.05 | 18 |
| AstraZeneca Pharmaceuticals LP | $66.48 | 3 |
| Inspire Medical Systems, Inc. | $48.61 | 2 |
| GENZYME CORPORATION | $33.41 | 1 |
| Axsome Therapeutics, Inc. | $31.73 | 1 |
| Insmed, Inc. | $26.09 | 1 |
| Azurity Pharmaceuticals, Inc. | $18.34 | 1 |
| Fisher & Paykel Healthcare Inc | $16.40 | 1 |
Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
THOMAS P STERN
NPI 1083639439 · CMS profile ID 185337
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
HUNTERSVILLE, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1083639439?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- THOMAS P STERN, NPI 1083639439, CMS profile ID 185337. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083639439?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). THOMAS P STERN, NPI 1083639439, CMS profile ID 185337. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083639439?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- THOMAS P STERN, NPI 1083639439, CMS profile ID 185337, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1083639439?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
86 matching records · $14,332.05 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–86 of 86.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Avadel CNS Pharmaceuticals, LLC | $13.75 | 07/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208542542 | CMS |
| Avadel CNS Pharmaceuticals, LLC | $13.75 | 07/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208542540 | CMS |
| Azurity Pharmaceuticals, Inc. | $18.34 | 07/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242679707 | CMS |
| JAZZ PHARMACEUTICALS INC. | $13.57 | 07/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234345527 | CMS |
| GlaxoSmithKline, LLC. | $6.86 | 06/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191002376 | CMS |
| JAZZ PHARMACEUTICALS INC. | $11.03 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234346373 | CMS |
| Avadel CNS Pharmaceuticals, LLC | $545.00 | 06/24/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208542538 | CMS |
| Axsome Therapeutics, Inc. | $31.73 | 06/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235739377 | CMS |
| JAZZ PHARMACEUTICALS INC. | $14.04 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234345121 | CMS |
| Fisher & Paykel Healthcare Inc | $16.40 | 05/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244153647 | CMS |
| Avadel CNS Pharmaceuticals, LLC | $23.94 | 05/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208542536 | CMS |
| JAZZ PHARMACEUTICALS INC. | $11.63 | 05/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234346207 | CMS |
| JAZZ PHARMACEUTICALS INC. | $13.29 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234345641 | CMS |
| JAZZ PHARMACEUTICALS INC. | $14.15 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234345055 | CMS |
| JAZZ PHARMACEUTICALS INC. | $10.60 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234346623 | CMS |
| JAZZ PHARMACEUTICALS INC. | $8.85 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234347107 | CMS |
| GlaxoSmithKline, LLC. | $4.58 | 04/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191805830 | CMS |
| JAZZ PHARMACEUTICALS INC. | $19.57 | 04/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234337547 | CMS |
| GlaxoSmithKline, LLC. | $8.72 | 03/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190899167 | CMS |
| GlaxoSmithKline, LLC. | $16.85 | 03/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191574421 | CMS |
| GlaxoSmithKline, LLC. | $4.28 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191121139 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.86 | 03/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214780725 | CMS |
| GlaxoSmithKline, LLC. | $15.93 | 02/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191334186 | CMS |
| GlaxoSmithKline, LLC. | $4.61 | 02/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190655746 | CMS |
| GlaxoSmithKline, LLC. | $3.92 | 02/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191066796 | CMS |
| Inspire Medical Systems, Inc. | $26.01 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251511680 | CMS |
| JAZZ PHARMACEUTICALS INC. | $16.75 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234341892 | CMS |
| JAZZ PHARMACEUTICALS INC. | $0.89 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234349236 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.38 | 02/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214776451 | CMS |
| GlaxoSmithKline, LLC. | $8.01 | 02/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191650909 | CMS |
| JAZZ PHARMACEUTICALS INC. | $150.00 | 01/28/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234303559 | CMS |
| JAZZ PHARMACEUTICALS INC. | $20.28 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234336407 | CMS |
| GlaxoSmithKline, LLC. | $4.17 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190740572 | CMS |
| GlaxoSmithKline, LLC. | $10.40 | 01/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190726658 | CMS |
| GlaxoSmithKline, LLC. | $110.39 | 01/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191366190 | CMS |
| JAZZ PHARMACEUTICALS INC. | $10.22 | 01/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234346721 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,661,665.19 | 468 |
| PY2024 | Principal investigator | $1,894,768.84 | 859 |
| PY2023 | Principal investigator | $926,087.97 | 207 |
| PY2022 | Principal investigator | $280,982.24 | 71 |
| PY2021 | Principal investigator | $90,582.08 | 25 |
| PY2020 | Principal investigator | $101,650.81 | 110 |
| PY2019 | Principal investigator | $165,124.47 | 127 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
468 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Avadel CNS Pharmaceuticals, LLC | $119,238.40 | 12/31/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) | No dispute reported | 06/30/2026 | 1208554245 |
| Principal investigator 1 | Alkermes, Inc. | $7,817.00 | 12/23/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613125 |
| Principal investigator 1 | Alkermes, Inc. | $5,741.00 | 12/23/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614190 |
| Principal investigator 1 | Alkermes, Inc. | $2,538.00 | 12/23/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618993 |
| Principal investigator 1 | Alkermes, Inc. | $70.00 | 12/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 12/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636313 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 12/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636315 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 12/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636317 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $16.24 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736925 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.32 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736927 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $28.05 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736929 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $30.10 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736931 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3.84 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736933 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $238.56 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736935 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $44.50 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736937 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3.56 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736939 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $237.40 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736941 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $30.10 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736943 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $44.00 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736945 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $35.60 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736947 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5.30 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736949 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $93.50 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736951 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $32.08 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736953 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.92 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736955 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $0.66 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736957 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2.31 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736959 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10.60 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736961 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $17.80 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736963 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.65 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736965 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $22.00 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736967 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $20.80 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736969 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $14.26 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736971 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.72 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736973 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $46.75 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736975 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $128.34 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736977 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $118.70 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736979 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $33.00 | 11/24/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736981 |
| Principal investigator 1 | Alkermes, Inc. | $2,359.00 | 11/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624566 |
| Principal investigator 1 | Alkermes, Inc. | $5,629.00 | 11/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626088 |
| Principal investigator 1 | Alkermes, Inc. | $314.00 | 11/10/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613980 |
| Principal investigator 1 | Alkermes, Inc. | $2,367.00 | 11/10/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614865 |
| Principal investigator 1 | Alkermes, Inc. | $2,164.00 | 11/10/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619471 |
| Principal investigator 1 | Alkermes, Inc. | $41.04 | 11/07/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617351 |
| Principal investigator 1 | Alkermes, Inc. | $27.36 | 11/07/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620994 |
| Principal investigator 1 | Alkermes, Inc. | $58.23 | 11/07/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626904 |
| Principal investigator 1 | PFIZER INC. | $18,950.00 | 11/04/2025 | Non-covered Recipient Entity Stern Research Partners | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228737340 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,027.04 | 11/03/2025 | Non-covered Recipient Entity STERN RESEARCH PARTNERS LLC | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223287851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 11/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636307 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 11/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636309 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 11/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636311 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,870.00 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744429 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,632.15 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744431 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10,868.25 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744435 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $456.00 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744437 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $70,645.00 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744439 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,852.20 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744443 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5,953.50 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744445 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $52,458.30 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744447 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $104,170.00 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744451 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6,820.70 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744453 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $9,600.00 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744455 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $15,120.00 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744459 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $32,400.00 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744461 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $9,784.80 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744463 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6,000.00 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744465 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $972.00 | 10/27/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744467 |
| Principal investigator 1 | Alkermes, Inc. | $314.00 | 10/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613321 |
| Principal investigator 1 | Alkermes, Inc. | $805.00 | 10/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614188 |
| Principal investigator 1 | Alkermes, Inc. | $3,097.00 | 10/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614625 |
| Principal investigator 1 | Alkermes, Inc. | $2,472.00 | 10/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617401 |
| Principal investigator 1 | Alkermes, Inc. | $5,741.00 | 10/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618037 |
| Principal investigator 1 | Alkermes, Inc. | $4,839.00 | 10/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621474 |
| Principal investigator 1 | Alkermes, Inc. | $7,665.00 | 10/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623694 |
| Principal investigator 1 | Alkermes, Inc. | $2,451.00 | 10/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625215 |
| Principal investigator 1 | GENZYME CORPORATION | $3,384.00 | 10/20/2025 | Non-covered Recipient Entity Stern Research Partners Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226088982 |
| Principal investigator 1 | Alkermes, Inc. | $1,300.00 | 10/15/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208622333 |
| Principal investigator 1 | Alkermes, Inc. | $2,000.00 | 10/15/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623490 |
| Principal investigator 1 | Alkermes, Inc. | $10,000.00 | 10/15/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625465 |
| Principal investigator 1 | Genentech, Inc. | $1,359.00 | 10/15/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211570084 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,895.00 | 10/13/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744433 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 10/13/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744441 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6,000.00 | 10/13/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744449 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 10/13/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744457 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 10/13/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744469 |
| Principal investigator 1 | PFIZER INC. | $4,425.40 | 10/11/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINEHUNTERSVILLE | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228728047 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 10/08/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615661 |
| Principal investigator 1 | Alkermes, Inc. | $5,521.00 | 10/08/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619725 |
| Principal investigator 1 | Alkermes, Inc. | $552.10 | 10/08/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625922 |
| Principal investigator 1 | Alkermes, Inc. | $1,342.00 | 10/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613127 |
| Principal investigator 1 | Alkermes, Inc. | $314.00 | 10/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621476 |
| Principal investigator 1 | Alkermes, Inc. | $314.00 | 10/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624806 |
| Principal investigator 1 | PFIZER INC. | $1,339.39 | 10/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINEHUNTERSVILLE | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228719713 |
| Principal investigator 1 | Alkermes, Inc. | $524.80 | 10/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617127 |
| Principal investigator 1 | Alkermes, Inc. | $191.52 | 10/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617735 |
| Principal investigator 1 | Alkermes, Inc. | $37.90 | 10/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618917 |
| Principal investigator 1 | Alkermes, Inc. | $58.23 | 10/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 10/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636301 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 10/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636303 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 10/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636305 |
| Principal investigator 1 | Alkermes, Inc. | $7,817.00 | 09/25/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617625 |
| Principal investigator 1 | Alkermes, Inc. | $2,359.00 | 09/25/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625055 |
| Principal investigator 1 | Alkermes, Inc. | $948.00 | 09/25/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626774 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,200.00 | 09/23/2025 | Non-covered Recipient Entity RESEARCH CAROLINA | A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, | No dispute reported | 06/30/2026 | 1192142264 |
| Principal investigator 1 | Alkermes, Inc. | $2,733.00 | 09/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615955 |
| Principal investigator 1 | Alkermes, Inc. | $2,733.00 | 09/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617233 |
| Principal investigator 1 | Alkermes, Inc. | $2,733.00 | 09/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623938 |
| Principal investigator 1 | Alkermes, Inc. | $2,733.00 | 09/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625059 |
| Principal investigator 1 | Alkermes, Inc. | $2,733.00 | 09/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626146 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $20,000.00 | 09/15/2025 | Non-covered Recipient Entity Stern Research Partners Llc | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype | No dispute reported | 06/30/2026 | 1226088976 |
| Principal investigator 1 | Alkermes, Inc. | $56.40 | 09/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615323 |
| Principal investigator 1 | Alkermes, Inc. | $119.25 | 09/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615731 |
| Principal investigator 1 | Alkermes, Inc. | $51.75 | 09/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619545 |
| Principal investigator 1 | Alkermes, Inc. | $172.25 | 09/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620241 |
| Principal investigator 1 | Alkermes, Inc. | $71.60 | 09/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623532 |
| Principal investigator 1 | Alkermes, Inc. | $112.80 | 09/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624622 |
| Principal investigator 1 | Alkermes, Inc. | $75.20 | 09/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625289 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,200.00 | 09/03/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744411 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 09/03/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744417 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $100,845.67 | 09/03/2025 | Non-covered Recipient Entity Stern Research Partners | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233744419 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,390.00 | 09/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223284931 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,780.00 | 09/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223284933 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,780.00 | 09/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223284935 |
| Principal investigator 1 | Verona Pharma, Inc. | $9,500.00 | 09/03/2025 | Non-covered Recipient Entity STERN RESEARCH PARTNERS LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891339 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,800.00 | 09/03/2025 | Non-covered Recipient Entity STERN RESEARCH PARTNERS LLC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891341 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 09/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636283 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 09/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636285 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 09/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636287 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $174.50 | 08/27/2025 | Non-covered Recipient Entity STERN RESEARCH PARTNERS | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185541360 |
| Principal investigator 1 | Alkermes, Inc. | $2,451.00 | 08/20/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613551 |
| Principal investigator 1 | Alkermes, Inc. | $5,629.00 | 08/20/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617021 |
| Principal investigator 1 | Alkermes, Inc. | $314.00 | 08/20/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624848 |
| Principal investigator 1 | Alkermes, Inc. | $805.00 | 08/20/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625527 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,156.20 | 08/18/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine, Pllc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226142841 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,901.30 | 08/14/2025 | Non-covered Recipient Entity RESEARCH CAROLINA | A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, | No dispute reported | 06/30/2026 | 1192142280 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,048.98 | 08/14/2025 | Non-covered Recipient Entity RESEARCH CAROLINA | A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, | No dispute reported | 06/30/2026 | 1192180419 |
| Principal investigator 1 | Alkermes, Inc. | $70.00 | 08/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615919 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,000.00 | 08/07/2025 | Non-covered Recipient Entity INTERSPOND LLC | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192180405 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 08/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636267 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 08/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636269 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 08/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636271 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636273 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636275 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636277 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636279 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $799.00 | 08/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636281 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283447 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,540.00 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283449 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,208.24 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283451 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283453 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283455 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $300.00 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283457 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $700.00 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283459 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,150.00 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283461 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,170.00 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | No dispute reported | 06/30/2026 | 1223283539 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,780.00 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | No dispute reported | 06/30/2026 | 1223283541 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $244.90 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283605 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,468.71 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283619 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,748.27 | 08/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223283621 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $18,748.60 | 07/31/2025 | Non-covered Recipient Entity RESEARCH CAROLINA | A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, | No dispute reported | 06/30/2026 | 1192142259 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $37,468.75 | 07/31/2025 | Non-covered Recipient Entity RESEARCH CAROLINA | A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, | No dispute reported | 06/30/2026 | 1192142273 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $38,819.00 | 07/29/2025 | Non-covered Recipient Entity STERN RESEARCH PARTNERS | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185541354 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $174.90 | 07/28/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636289 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 07/28/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 07/28/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636293 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.28 | 07/28/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636295 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $65.55 | 07/28/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636297 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 07/28/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636299 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $146.93 | 07/25/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744413 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,895.00 | 07/25/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744415 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,070.00 | 07/25/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744421 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 07/25/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744425 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,000.00 | 07/25/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744427 |
| Principal investigator 1 | Alkermes, Inc. | $3,097.00 | 07/23/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615951 |
| Principal investigator 1 | Alkermes, Inc. | $7,665.00 | 07/23/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618091 |
| Principal investigator 1 | Alkermes, Inc. | $2,472.00 | 07/23/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624612 |
| Principal investigator 1 | Alkermes, Inc. | $4,839.00 | 07/23/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625057 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 07/21/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613341 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 07/21/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618299 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,000.00 | 07/21/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine, Pllc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226142818 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 07/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613143 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 07/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618093 |
| Principal investigator 1 | Alkermes, Inc. | $947.00 | 07/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618095 |
| Principal investigator 1 | Alkermes, Inc. | $3,751.00 | 07/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626350 |
| Principal investigator 1 | GENZYME CORPORATION | $1,299.00 | 07/14/2025 | Non-covered Recipient Entity Stern Research Partners Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226088960 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,156.20 | 07/14/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine, Pllc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226142815 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,465.39 | 07/11/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744423 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $32,527.40 | 07/11/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | No dispute reported | 06/30/2026 | 1223282550 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,027.04 | 07/11/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223282560 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250,222.50 | 07/04/2025 | Non-covered Recipient Entity RESEARCH CAROLINA | A RANDOMIZED, NON-INFERIORITY, DOUBLE-BLIND, CONTROLLED, SINGLE-DOSE, | No dispute reported | 06/30/2026 | 1192142269 |
| Principal investigator 1 | Alkermes, Inc. | $8.04 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613379 |
| Principal investigator 1 | Alkermes, Inc. | $115.65 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614022 |
| Principal investigator 1 | Alkermes, Inc. | $64.25 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614913 |
| Principal investigator 1 | Alkermes, Inc. | $111.36 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617845 |
| Principal investigator 1 | Alkermes, Inc. | $2.61 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618109 |
| Principal investigator 1 | Alkermes, Inc. | $56.10 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618111 |
| Principal investigator 1 | Alkermes, Inc. | $36.40 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619543 |
| Principal investigator 1 | Alkermes, Inc. | $3.50 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620035 |
| Principal investigator 1 | Alkermes, Inc. | $19.26 | 07/02/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620037 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 07/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636261 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 07/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636263 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 07/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636265 |
| Principal investigator 1 | Alkermes, Inc. | $93.50 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208612895 |
| Principal investigator 1 | Alkermes, Inc. | $77.10 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613189 |
| Principal investigator 1 | Alkermes, Inc. | $16.00 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613595 |
| Principal investigator 1 | Alkermes, Inc. | $1.96 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613768 |
| Principal investigator 1 | Alkermes, Inc. | $23.52 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614000 |
| Principal investigator 1 | Alkermes, Inc. | $449.75 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614284 |
| Principal investigator 1 | Alkermes, Inc. | $3.50 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614288 |
| Principal investigator 1 | Alkermes, Inc. | $162.05 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614422 |
| Principal investigator 1 | Alkermes, Inc. | $4.27 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614639 |
| Principal investigator 1 | Alkermes, Inc. | $0.87 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614655 |
| Principal investigator 1 | Alkermes, Inc. | $1.71 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614869 |
| Principal investigator 1 | Alkermes, Inc. | $65.45 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614875 |
| Principal investigator 1 | Alkermes, Inc. | $3.50 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614957 |
| Principal investigator 1 | Alkermes, Inc. | $4.27 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615099 |
| Principal investigator 1 | Alkermes, Inc. | $51.55 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615341 |
| Principal investigator 1 | Alkermes, Inc. | $93.50 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615673 |
| Principal investigator 1 | Alkermes, Inc. | $25.48 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615709 |
| Principal investigator 1 | Alkermes, Inc. | $141.35 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615755 |
| Principal investigator 1 | Alkermes, Inc. | $13.72 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616141 |
| Principal investigator 1 | Alkermes, Inc. | $1.71 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616353 |
| Principal investigator 1 | Alkermes, Inc. | $51.55 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616455 |
| Principal investigator 1 | Alkermes, Inc. | $2.10 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616625 |
| Principal investigator 1 | Alkermes, Inc. | $15.39 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616757 |
| Principal investigator 1 | Alkermes, Inc. | $10.90 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617043 |
| Principal investigator 1 | Alkermes, Inc. | $89.95 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617057 |
| Principal investigator 1 | Alkermes, Inc. | $2.14 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617085 |
| Principal investigator 1 | Alkermes, Inc. | $25.70 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617269 |
| Principal investigator 1 | Alkermes, Inc. | $3.15 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617457 |
| Principal investigator 1 | Alkermes, Inc. | $145.60 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617465 |
| Principal investigator 1 | Alkermes, Inc. | $109.20 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617671 |
| Principal investigator 1 | Alkermes, Inc. | $4.55 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617673 |
| Principal investigator 1 | Alkermes, Inc. | $28.14 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618567 |
| Principal investigator 1 | Alkermes, Inc. | $77.10 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618625 |
| Principal investigator 1 | Alkermes, Inc. | $2.45 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618627 |
| Principal investigator 1 | Alkermes, Inc. | $12.84 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618643 |
| Principal investigator 1 | Alkermes, Inc. | $37.12 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618855 |
| Principal investigator 1 | Alkermes, Inc. | $4.20 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619105 |
| Principal investigator 1 | Alkermes, Inc. | $171.75 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619113 |
| Principal investigator 1 | Alkermes, Inc. | $17.12 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619331 |
| Principal investigator 1 | Alkermes, Inc. | $50.15 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619335 |
| Principal investigator 1 | Alkermes, Inc. | $19.60 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619341 |
| Principal investigator 1 | Alkermes, Inc. | $127.40 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619577 |
| Principal investigator 1 | Alkermes, Inc. | $17.64 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619777 |
| Principal investigator 1 | Alkermes, Inc. | $34.35 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619829 |
| Principal investigator 1 | Alkermes, Inc. | $74.24 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620069 |
| Principal investigator 1 | Alkermes, Inc. | $4.35 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620211 |
| Principal investigator 1 | Alkermes, Inc. | $17.12 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620295 |
| Principal investigator 1 | Alkermes, Inc. | $12.06 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620451 |
| Principal investigator 1 | Alkermes, Inc. | $185.60 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620922 |
| Principal investigator 1 | Alkermes, Inc. | $0.80 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621140 |
| Principal investigator 1 | Alkermes, Inc. | $11.76 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621152 |
| Principal investigator 1 | Alkermes, Inc. | $58.80 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621160 |
| Principal investigator 1 | Alkermes, Inc. | $54.60 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621554 |
| Principal investigator 1 | Alkermes, Inc. | $0.35 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621748 |
| Principal investigator 1 | Alkermes, Inc. | $182.00 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621983 |
| Principal investigator 1 | Alkermes, Inc. | $182.00 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621985 |
| Principal investigator 1 | Alkermes, Inc. | $38.47 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622135 |
| Principal investigator 1 | Alkermes, Inc. | $74.80 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622755 |
| Principal investigator 1 | Alkermes, Inc. | $50.15 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622854 |
| Principal investigator 1 | Alkermes, Inc. | $32.70 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623090 |
| Principal investigator 1 | Alkermes, Inc. | $12.85 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623092 |
| Principal investigator 1 | Alkermes, Inc. | $15.39 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623504 |
| Principal investigator 1 | Alkermes, Inc. | $10.50 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623572 |
| Principal investigator 1 | Alkermes, Inc. | $77.10 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623574 |
| Principal investigator 1 | Alkermes, Inc. | $8.56 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623778 |
| Principal investigator 1 | Alkermes, Inc. | $46.75 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623916 |
| Principal investigator 1 | Alkermes, Inc. | $40.20 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623928 |
| Principal investigator 1 | Alkermes, Inc. | $74.90 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624026 |
| Principal investigator 1 | Alkermes, Inc. | $77.10 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624214 |
| Principal investigator 1 | Alkermes, Inc. | $46.75 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624394 |
| Principal investigator 1 | Alkermes, Inc. | $11.76 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624402 |
| Principal investigator 1 | Alkermes, Inc. | $17.12 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624464 |
| Principal investigator 1 | Alkermes, Inc. | $1.71 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624820 |
| Principal investigator 1 | Alkermes, Inc. | $2.10 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624885 |
| Principal investigator 1 | Alkermes, Inc. | $46.75 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625239 |
| Principal investigator 1 | Alkermes, Inc. | $1.71 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625467 |
| Principal investigator 1 | Alkermes, Inc. | $0.70 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625798 |
| Principal investigator 1 | Alkermes, Inc. | $15.39 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626100 |
| Principal investigator 1 | Alkermes, Inc. | $12.06 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626114 |
| Principal investigator 1 | Alkermes, Inc. | $1.74 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626116 |
| Principal investigator 1 | Alkermes, Inc. | $72.80 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626196 |
| Principal investigator 1 | Alkermes, Inc. | $19.60 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626212 |
| Principal investigator 1 | Alkermes, Inc. | $1.74 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626336 |
| Principal investigator 1 | Alkermes, Inc. | $74.24 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626604 |
| Principal investigator 1 | Alkermes, Inc. | $38.55 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626606 |
| Principal investigator 1 | Alkermes, Inc. | $15.39 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626740 |
| Principal investigator 1 | Alkermes, Inc. | $38.47 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626744 |
| Principal investigator 1 | Alkermes, Inc. | $3.92 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626772 |
| Principal investigator 1 | Alkermes, Inc. | $5.45 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626824 |
| Principal investigator 1 | Alkermes, Inc. | $25.00 | 06/18/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626866 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $10.70 | 06/11/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736917 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.72 | 06/11/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736919 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $0.96 | 06/11/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736921 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $0.48 | 06/11/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736923 |
| Principal investigator 1 | Alkermes, Inc. | $72.00 | 06/07/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624724 |
| Principal investigator 1 | Alkermes, Inc. | $51.80 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614132 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614457 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614459 |
| Principal investigator 1 | Alkermes, Inc. | $48.00 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614801 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615481 |
| Principal investigator 1 | Alkermes, Inc. | $341.02 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616189 |
| Principal investigator 1 | Alkermes, Inc. | $35.00 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616611 |
| Principal investigator 1 | Alkermes, Inc. | $135.00 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621134 |
| Principal investigator 1 | Alkermes, Inc. | $64.94 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621402 |
| Principal investigator 1 | Alkermes, Inc. | $341.02 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625559 |
| Principal investigator 1 | Alkermes, Inc. | $220.78 | 06/06/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626186 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $785.00 | 06/01/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220636259 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744387 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,479.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744389 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $8,327.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744391 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5,067.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744393 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6,000.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744395 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $205.20 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744397 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,027.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744399 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,000.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744401 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,500.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744403 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $300.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744405 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,740.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744407 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $9,986.00 | 05/23/2025 | Non-covered Recipient Entity Stern Research Partners | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233744409 |
| Principal investigator 1 | Alkermes, Inc. | $495.41 | 05/21/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613403 |
| Principal investigator 1 | GENZYME CORPORATION | $1,787.00 | 05/21/2025 | Non-covered Recipient Entity Stern Research Partners Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226085493 |
| Principal investigator 1 | Alkermes, Inc. | $2,551.00 | 05/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613449 |
| Principal investigator 1 | Alkermes, Inc. | $802.00 | 05/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614120 |
| Principal investigator 1 | Alkermes, Inc. | $2,551.00 | 05/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614787 |
| Principal investigator 1 | Alkermes, Inc. | $2,297.00 | 05/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618451 |
| Principal investigator 1 | Alkermes, Inc. | $1,783.00 | 05/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619879 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 05/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620564 |
| Principal investigator 1 | Alkermes, Inc. | $2,309.00 | 05/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620980 |
| Principal investigator 1 | Alkermes, Inc. | $2,551.00 | 05/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622487 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 05/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623812 |
| Principal investigator 1 | Alkermes, Inc. | $3,751.00 | 05/19/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625629 |
| Principal investigator 1 | Alkermes, Inc. | $947.00 | 05/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614775 |
| Principal investigator 1 | Alkermes, Inc. | $947.00 | 05/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615005 |
| Principal investigator 1 | Alkermes, Inc. | $947.00 | 05/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618187 |
| Principal investigator 1 | Alkermes, Inc. | $947.00 | 05/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619147 |
| Principal investigator 1 | Alkermes, Inc. | $947.00 | 05/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621184 |
| Principal investigator 1 | Alkermes, Inc. | $947.00 | 05/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622479 |
| Principal investigator 1 | Alkermes, Inc. | $947.00 | 05/16/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622892 |
| Principal investigator 1 | GENZYME CORPORATION | $1,787.00 | 05/12/2025 | Non-covered Recipient Entity Stern Research Partners Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226085489 |
| Principal investigator 1 | Genentech, Inc. | $7,155.00 | 05/07/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211570081 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10,362.24 | 04/23/2025 | Non-covered Recipient Entity HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) | No dispute reported | 06/30/2026 | 1185541356 |
| Principal investigator 1 | Alkermes, Inc. | $1,045.00 | 04/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613317 |
| Principal investigator 1 | Alkermes, Inc. | $1,045.00 | 04/22/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626966 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,378.60 | 04/11/2025 | Non-covered Recipient Entity Stern Research Partners Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226085440 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,310.20 | 04/11/2025 | Non-covered Recipient Entity Stern Research Partners Llc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226085444 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,496.00 | 04/11/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP | A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | No dispute reported | 06/30/2026 | 1223277888 |
| Principal investigator 1 | Alkermes, Inc. | $61.60 | 04/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613199 |
| Principal investigator 1 | Alkermes, Inc. | $77.10 | 04/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616841 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,378.60 | 04/02/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine, Pllc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226142708 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,310.20 | 04/02/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine, Pllc | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies | No dispute reported | 06/30/2026 | 1226142714 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $29,033.88 | 03/28/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) | No dispute reported | 06/30/2026 | 1185541362 |
| Principal investigator 1 | GENZYME CORPORATION | $1,299.00 | 03/24/2025 | Non-covered Recipient Entity Stern Research Partners Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226085423 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 03/20/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626330 |
| Principal investigator 1 | GENZYME CORPORATION | $19,899.00 | 03/06/2025 | Non-covered Recipient Entity Stern Research Partners Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226085419 |
| Principal investigator 1 | Alkermes, Inc. | $56.85 | 03/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613962 |
| Principal investigator 1 | Alkermes, Inc. | $113.34 | 03/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615421 |
| Principal investigator 1 | Alkermes, Inc. | $259.54 | 03/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616075 |
| Principal investigator 1 | Alkermes, Inc. | $119.36 | 03/03/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622976 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,496.00 | 02/21/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223275437 |
| Principal investigator 1 | GENZYME CORPORATION | $1,299.00 | 02/18/2025 | Non-covered Recipient Entity Advanced Respiratory And Sleep Medicine, Pllc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226142731 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614547 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615819 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618671 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619363 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619365 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619619 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619623 |
| Principal investigator 1 | Alkermes, Inc. | $650.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620968 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622673 |
| Principal investigator 1 | Alkermes, Inc. | $650.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622906 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623146 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623810 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624298 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625834 |
| Principal investigator 1 | Alkermes, Inc. | $6.40 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613948 |
| Principal investigator 1 | Alkermes, Inc. | $2,479.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614517 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614605 |
| Principal investigator 1 | Alkermes, Inc. | $162.05 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614835 |
| Principal investigator 1 | Alkermes, Inc. | $2,309.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615349 |
| Principal investigator 1 | Alkermes, Inc. | $12.85 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615859 |
| Principal investigator 1 | Alkermes, Inc. | $12.85 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615863 |
| Principal investigator 1 | Alkermes, Inc. | $2,297.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616223 |
| Principal investigator 1 | Alkermes, Inc. | $855.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616651 |
| Principal investigator 1 | Alkermes, Inc. | $52.80 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616965 |
| Principal investigator 1 | Alkermes, Inc. | $1.71 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617165 |
| Principal investigator 1 | Alkermes, Inc. | $167.05 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617559 |
| Principal investigator 1 | Alkermes, Inc. | $412.40 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618025 |
| Principal investigator 1 | Alkermes, Inc. | $44.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618963 |
| Principal investigator 1 | Alkermes, Inc. | $25.65 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208619721 |
| Principal investigator 1 | Alkermes, Inc. | $38.55 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620604 |
| Principal investigator 1 | Alkermes, Inc. | $9.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621236 |
| Principal investigator 1 | Alkermes, Inc. | $64.25 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621440 |
| Principal investigator 1 | Alkermes, Inc. | $2,297.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621562 |
| Principal investigator 1 | Alkermes, Inc. | $47.75 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621652 |
| Principal investigator 1 | Alkermes, Inc. | $44.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625203 |
| Principal investigator 1 | Alkermes, Inc. | $89.95 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625423 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626218 |
| Principal investigator 1 | Alkermes, Inc. | $100.30 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626494 |
| Principal investigator 1 | Alkermes, Inc. | $15.39 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626952 |
| Principal investigator 1 | Alkermes, Inc. | $44.00 | 02/12/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208626958 |
| Principal investigator 1 | Alkermes, Inc. | $82.08 | 02/10/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616333 |
| Principal investigator 1 | Alkermes, Inc. | $77.64 | 02/10/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618537 |
| Principal investigator 1 | Alkermes, Inc. | $228.53 | 02/10/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623224 |
| Principal investigator 1 | Alkermes, Inc. | $52.48 | 02/10/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624560 |
| Principal investigator 1 | Genentech, Inc. | $8,544.00 | 02/07/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211570073 |
| Principal investigator 1 | Genentech, Inc. | $6,679.00 | 02/07/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211570077 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $873.00 | 02/07/2025 | Non-covered Recipient Entity INTERSPOND LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192180399 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,176.12 | 02/03/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736879 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $35.00 | 01/31/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736854 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $42.00 | 01/31/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736862 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.00 | 01/31/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736881 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.00 | 01/31/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736895 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,008.04 | 01/29/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185541358 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,500.00 | 01/22/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736842 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $9,986.00 | 01/22/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736876 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,479.00 | 01/22/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736887 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,000.00 | 01/22/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736899 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $993.00 | 01/22/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736901 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $8,327.00 | 01/22/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736913 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616003 |
| Principal investigator 1 | Alkermes, Inc. | $855.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618423 |
| Principal investigator 1 | Alkermes, Inc. | $802.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618425 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618885 |
| Principal investigator 1 | Alkermes, Inc. | $7,740.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618889 |
| Principal investigator 1 | Alkermes, Inc. | $855.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619135 |
| Principal investigator 1 | Alkermes, Inc. | $2,479.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619847 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622229 |
| Principal investigator 1 | Alkermes, Inc. | $2,479.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622876 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622878 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623384 |
| Principal investigator 1 | Alkermes, Inc. | $5,521.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624036 |
| Principal investigator 1 | Alkermes, Inc. | $2,297.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624680 |
| Principal investigator 1 | Alkermes, Inc. | $312.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625840 |
| Principal investigator 1 | Alkermes, Inc. | $2,297.00 | 01/17/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626404 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $685.93 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736844 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,306.80 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736846 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $831.60 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736848 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,141.45 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736850 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $11,029.50 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736852 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736856 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $341.55 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736858 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736864 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736866 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736868 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736870 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736872 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,906.20 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736874 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736885 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $699.30 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736889 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736891 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736893 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736897 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $831.60 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736903 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736905 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736907 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $271.35 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736909 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $11,029.50 | 01/17/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233736915 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,490.18 | 01/13/2025 | Non-covered Recipient Entity INTERSPOND LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192180410 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,852.57 | 01/10/2025 | Non-covered Recipient Entity INTERSPOND LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1192180394 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,965.00 | 01/10/2025 | Non-covered Recipient Entity INTERSPOND LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1192180402 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,980.00 | 01/10/2025 | Non-covered Recipient Entity INTERSPOND LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1192180414 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $13.15 | 01/06/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736860 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $13.15 | 01/06/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736883 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $8.90 | 01/06/2025 | Non-covered Recipient Entity Advanced Respiratory and Sleep Medicine, PLLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233736911 |
| Principal investigator 1 | Alkermes, Inc. | $15,156.91 | 01/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208627122 |
| Principal investigator 1 | Alkermes, Inc. | $10,678.47 | 01/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208627198 |
| Principal investigator 1 | Alkermes, Inc. | $16,536.51 | 01/01/2025 | Non-covered Recipient Entity ADVANCED RESPIRATORY AND SLEEP MEDICINE, PLLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208627268 |